Harpoon Therapeutics, Inc. (HARP)

Market Cap	27.87M
Revenue (ttm)	31.92M
Net Income (ttm)	-67.73M
Shares Out	37.45M
EPS (ttm)	-2.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197,513
Open	0.685
Previous Close	0.691
Day's Range	0.685 - 0.750
52-Week Range	0.586 - 5.160
Beta	1.56
Analysts	Buy
Price Target	6.95 (+833.89%)
Earnings Date	May 11, 2023

About HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II cl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2019
• Employees: 86
• Stock Exchange: NASDAQ
• Ticker Symbol: HARP

Financial Performance

In 2022, HARP's revenue was $31.92 million, an increase of 34.92% compared to the previous year's $23.65 million. Losses were -$67.73 million, -41.97% less than in 2021.

Analyst Forecast

According to 14 analysts, the average rating for HARP stock is "Buy." The 12-month stock price forecast is $6.95, which is an increase of 833.89% from the latest price.

Price Target

$6.95

(833.89% upside)

Analyst Consensus: Buy